Ocrelizumab in multiple sclerosis: markers and mechanisms
Lancet Neurol. 2017 Apr;16(4):259-261. doi: 10.1016/S1474-4422(17)30048-0.
|Authors/Editors:||Hohlfeld R, Meinl E.|
The results of three phase 3 trials of ocrelizumab, a humanised monoclonal antibody targeting the CD20 marker in B cells, have just been reported.1 ; 2 Ocrelizumab not only showed beneficial effects in patients with relapsing-remitting multiple sclerosis (RRMS), but also in those with primary progressive multiple sclerosis (PPMS).2 Approval of ocrelizumab for both indications is expected to be announced soon; this drug will then become the first immunomodulatory agent ever approved for the treatment of PPMS.